

SYNTHESIS AND EVALUATION OF $^{105}\text{RHODIUM(III)}$ COMPLEXES DERIVED FROM DIAMINODITHIOETHER (DADTE) LIGANDS

Zeynep Akgun

Dr. Susan Z. Lever, Dissertation Supervisor

ABSTRACT

Seven analogues of tetradentate acyclic diaminodithioether (DADTE) ligands were synthesized and characterized. $\text{R}_2\text{SC}(\text{R}_1)_2\text{CH}_n\text{N}(\text{CH}_2)_m\text{NCH}_n((\text{R}_1)_2\text{C})\text{SR}_2$ **222-gdm (L3)**: $m = 1, n = 1, \text{R}_1 = -\text{CH}_3$ and $\text{R}_2 = -\text{H}$; **222-gdm-pmBz (L4)**: $m = 1, n = 1, \text{R}_1 = -\text{CH}_3, \text{R}_2 = -\text{CH}_2\text{C}_6\text{H}_5\text{OCH}_3$; **232-gdm-pmBz (L7)**: $m = 2, n = 1, \text{R}_1 = -\text{CH}_3, \text{R}_2 = -\text{CH}_2\text{C}_6\text{H}_5\text{OCH}_3$, **232-gdm-Met (L8)**: $m = 2, n = 1, \text{R}_1 = -\text{CH}_3, \text{R}_2 = -\text{CH}_3$, **232-Met (L10)** $m = 2, n = 1, \text{R}_1 = -\text{H}, \text{R}_2 = -\text{CH}_3$, **323-Met (L12)**: $m = 1, n = 2, \text{R}_1 = -\text{H}, \text{R}_2 = -\text{CH}_3$ and **333-Met (L14)**: $m = 2, n = 2, \text{R}_1 = -\text{H}, \text{R}_2 = -\text{CH}_3$. Rh(III) complexes of these DADTE ligands were prepared and the effect of the ligand backbone size on the configuration (*cis* and/or *trans*) has been studied. ^{105}Rh radiolabeling studies were performed in order to investigate the optimum criteria for an ideal chelate such as high thermodynamic stability and kinetic inertness. Also, it is desirable that a single isomer with low lipophilicity properties is formed after complexation of the chelate. Complexation of **232-gdm-Met** with ^{105}Rh yielded a complex that fulfilled the minimum criteria. Coupling studies of **232-gdm-Met** to Bombesin(7-14)

analogues, Ahx-Met¹⁴-BBN(7-14) and Ahx-NLeu¹⁴-BBN(7-14), via an alternative approach have been accomplished. Finally, radiolabeling studies with **232-gdm-Met**-Ahx-BBN(7-14) analogues were investigated to achieve an efficient ¹⁰⁵Rh labeled BBN based target specific radiopharmaceutical.

Structural changes on the DADTE ligand system have been effected to provide a Rh(III)-DADTE complex with optimum properties for an ideal chelate for targeted therapy applications. The alternative approach developed to attach the ligands to peptides yields ¹⁰⁵Rh labeled Bombesin(7-14) without needing further functionalization on the ligand.